BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231009
DTEND;VALUE=DATE:20231011
DTSTAMP:20260516T073401
CREATED:20230810T115308Z
LAST-MODIFIED:20230810T115430Z
UID:37608-1696809600-1696982399@www.pharmajournalist.com
SUMMARY:Wearable Injectors and Connected Devices Conference & Expo
DESCRIPTION:Wearable Injectors and Connected Devices Conference & Expo \n9 – 10 October 2023 | London\, UK \nhttp://www.wearable-injectors.co.uk/PharmaJournalist-EL \nStrategies to advance digital health and on-body drug devices for large volume delivery \nSAE Media Group are proud to announce the 4th annual Wearable Injectors and Connected Devices conference. As the need for at home self-administration and routes for delivery of time-dependent and high-volume drug delivery grows\, on-body injectors and connected devices hold great opportunity. \nThe conference will delve into on-body device design and development\, enhancing digital connectivity for injectable devices\, strategic approaches to wearable device design\, regulatory considerations and primary container considerations for large volume delivery systems. \nAs part of SAE Media Group’s leading Injectable series of conferences\, we bring together high-level experts from big pharma and device developers to network and share knowledge to advance R&D. The two-day conference will not only bring you high-quality key insights needed to enhance your wearable devices and connected product portfolio but will also give you the opportunity to network with key players throughout the industry. We hope to welcome you to this must attend event in October 2023! \nBenefits of Attending: \n\nEngage with key regulatory updates surrounding digital health and medical devices\nDiscover advances in device design and development for large volume delivery via on-body injectors\nExplore the key drivers of novel drug products for the development for on-body injectors\nHear insights into the growing potential of digital health to improve patient experience and treatment\nDevelop your understanding of design strategies for connectivity and digital health\n\nDelegates will have the opportunity to network with the following companies: \n\nJohnson & Johnson\nBiogen\nAstraZeneca\nMerck KGaA\nNovartis\nNovo Nordisk\nBoehringer Ingelheim\n\nAnd many more!! \nWho Should Attend: \n\nExecutives\, Directors\, VPs\, Heads\, Principals\, Managers of:\nDrug-Delivery Developers\nAutoinjectors\nDevice Engineering\nHuman Factors\nInjectables\nPackaging\nRegulatory Affairs\nConnectivity\nMedical Device Data\nNovel Product Technology\nSmart Device Developers\nDevice Safety Solution Providers\nor anyone who works with Wearable Devices/ On-Body Injectors within pharmaceuticals\, biotech\, device developers and solution providers.\n\nThe two-day conference will bring you high-quality insights and industry connections on the latest advances in wearable injectors and connectivity\, and a platform for exchanging ideas.
URL:https://www.pharmajournalist.com/event/wearable-injectors-and-connected-devices-conference-expo/
LOCATION:Hilton London Kensington\, 179-199 Holland Park Ave\, London\, W11 4UL\, United Kingdom
ORGANIZER;CN="SAE MEDIA GROUP":MAILTO:events@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231010
DTEND;VALUE=DATE:20231013
DTSTAMP:20260516T073401
CREATED:20230628T105645Z
LAST-MODIFIED:20230628T105645Z
UID:37366-1696896000-1697155199@www.pharmajournalist.com
SUMMARY:6th Neuropsychiatric Drug Development Summit
DESCRIPTION:The Definitive Industry Forum for Spearheading Non-Psychedelic & Psychedelic R&D \n2023 is booming with novel psychiatric R&D and the promise of precision medicine for neuropsychiatric patients. Pipelines are gaining momentum\, with notable approvals on the horizon\, as unmet needs in PTSD\, bipolar\, anxiety\, schizophrenia\, depression\, and ADHD become greater and greater. There is\, therefore\, a huge deal of novel and promising research to be discussed this October at the 6th Neuropsychiatric Drug Development Summit. \nWith discovery\, preclinical\, translational\, and clinical scientists from the likes of Biogen\, Otsuka\, AbbVie\, Genentech\, Lundbeck\, Delix Therapeutics\, Atai\, Gilgamesh\, and Cerevel Therapeutics\, don’t miss the field’s favorite conference\, specifically dedicated to biopharma’s most pressing challenges of de-risking the translational gap and advancing transformative neuropsychiatric candidates through the clinic. \nTo know more visit: https://ter.li/sar413
URL:https://www.pharmajournalist.com/event/6th-neuropsychiatric-drug-development-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR